4Cl-iBF Stats & Data

• Extreme potency: doses are in micrograms. Consumer‑grade 0.001 g (1 mg) scales are not reliable at this range; even 0.1 mg readability devices may be inaccurate. Use volumetric dosing: dissolve a known mass into a measured volume and measure doses by volume; label concentrations. Never eyeball powder.

• Combining with other depressants (alcohol, benzodiazepines, Z‑drugs, GHB/GBL) markedly raises the risk of fatal respiratory depression; avoid these combinations.

• Gabapentin/pregabalin with opioids increases overdose and respiratory‑depression risk in population studies; avoid or use only under medical oversight.

• Tramadol with opioids increases seizure and serotonin‑toxicity risk; combination is unsafe.

• DXM with opioids is considered a dangerous combo (additive CNS depression and other risks).

• MAOIs should be avoided for at least 14 days; caution with SSRIs/SNRIs due to rare but reported serotonin toxicity with fentanyl.

• Rapid IV bolus of fentanyl‑class drugs can precipitate chest‑wall rigidity and difficult ventilation; if someone injects despite risks, slow, incremental administration reduces (but does not eliminate) risk.

• Naloxone reverses toxicity but may require repeated doses or infusion for potent/longer‑acting opioids; always call emergency services and monitor after reversal.

• Test strips: common FTS detect fentanyl and certain analogues but not all; they give a binary result and cannot quantify potency. A negative does not guarantee safety; a positive does not reveal which analogue.

• Unregulated opioid samples often contain benzodiazepine‑related drugs or ultra‑potent opioids (e.g., nitazenes), massively increasing overdose risk. Do not use alone; have naloxone present and a trained observer.

• Safer‑use injection practices (if used): sterile equipment, use a needle/syringe program, rotate sites, and seek medical care early for infections.

• Oral (swallowed) fentanyl has low bioavailability; clinically, transmucosal routes are used for fentanyl. By analogy, sublingual/buccal routes for some analogues may have higher efficiency than swallowing, but individual kinetics for 4Cl‑iBF are unknown—start low and avoid redosing during the first hour.

• Overdose recognition: unresponsive, slow/shallow or stopped breathing, blue lips, pinpoint pupils. Call emergency services immediately; place in recovery position and administer naloxone if available.